Oral Omega 3 Drusen: A phase II randomized, double-mask study to establish the safety and efficacy of High-Dose Oral Omega 3 in subjects with high-risk drusen secondary to dry age-related macular degeneration 26/03/2013
Description
The objectives of this study are to evaluate the safety and efficacy of High-Dose Oral Omega 3 on the Photoreceptors/Retinal Pigment Epithelium/Bruch’s membrane complex in subjects with high-risk drusen secondary to age-related macular degeneration and to evaluate whether improvement in visual function occurs and progression to advanced stages of AMD is delayed.
Intravitreal injectionsDry or atrophic AMDExudative or wet AMDRetina scanAutofluorescenceMicroperimetryFluorescein angiographyOptical coherence tomographyAuthor
Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Director
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal
01/01/2015FOVISTA: Clinical Trial for subfoveal neovascular age-related macular degeneration
19/03/2014Clinical trial in antiretroviral-naive patients with choroidal neovascularization secondary to AMD
31/03/2014Phase III Study of Lampalizumab in patients with geographic atrophy secondary to AMD
20/12/2014MPL4 GA: A phase I study in subjects with geographic atrophy secondary to dry age-related macular degeneration
